MAPT and Alzheimer disease: Neurodegeneration, along with Amyloid-β (Aβ) deposition and pathological tau, are currently the main biomarkers for neuropathological change in the AD field (Pini et al., 2016), as defined by the ATN classification (Amyloid, Tau and Neurodegeneration; Jack et al., 2018).